Does semaglutide cause constipation?

Yes, constipation is a recognized semaglutide side effect. In STEP 1, 23.4% of participants receiving semaglutide 2.4 mg reported it, compared with 9.5% receiving placebo. It appeared most often during initiation and dose escalation in pooled STEP data. An individual's likelihood also depends on baseline bowel habits, food and fluid intake, activity and other medications.

How long does semaglutide constipation last?

The pooled STEP 1–3 analysis reported a median duration of 47 days with semaglutide, compared with 35 days on placebo. That midpoint does not mean every episode lasts seven weeks. Some resolve sooner, while others persist. Symptoms commonly begin during initiation or escalation, and constipation prevalence in those trials levelled off around week 10.

What can help with constipation on semaglutide?

A prescriber will usually review steady fluid intake, a gradual increase in fibre from food, and regular movement that fits the patient's abilities. The clinician may also check other medications and medical causes. If symptoms followed a dose increase, slower escalation, a lower tolerated dose or a temporary hold may be considered by the prescriber rather than attempted independently.

When should constipation on semaglutide be reported?

Promptly report constipation that is severe or persistent, especially when it comes with repeated vomiting, escalating abdominal pain, marked swelling, inability to keep fluids down, or many days without a bowel movement. Severe pain or vomiting with an inability to pass stool or gas calls for urgent assessment because those symptoms can point to obstruction rather than ordinary constipation.

Should the semaglutide dose change because of constipation?

Only the prescribing clinician should make that decision. The timing and severity of symptoms, the most recent escalation, other medicines and the reason for treatment all matter. A clinician may allow more time at a tolerated dose, reduce it or pause treatment, but constipation does not lead to the same decision for everyone and the dose should not be changed independently.

Semaglutide Constipation: What Helps

Semaglutide constipation is common, especially while treatment is starting or the dose is increasing. For most people it is manageable and becomes less prominent as the body adjusts, but it often moves on a slower clock than nausea or diarrhea. A prescriber will usually look first at fluid, food-based fibre, movement and the pace of dose escalation. Going many days without a bowel movement, particularly with vomiting or severe pain, is a reason to call rather than wait.

Constipation is one part of the medicine's gastrointestinal profile. The broader semaglutide side-effects guide covers the rest without turning every new symptom into the same problem.

How common is semaglutide constipation?

In STEP 1, a 68-week trial in 1,961 adults with overweight or obesity and no diabetes, 23.4% of participants assigned to semaglutide 2.4 mg reported constipation, compared with 9.5% assigned to placebo. Those are trial rates, not a prediction for one person, but the comparison shows that the drug contributed more than background constipation alone (Wilding et al., New England Journal of Medicine, 2021).

A pooled analysis of STEP 1–3 found a similar pattern: 24.2% with semaglutide versus 11.1% with placebo. Gastrointestinal events appeared most often during or shortly after dose escalation. Most were mild to moderate, yet constipation lasted longer than the other common events: its median duration was 47 days with semaglutide and 35 days with placebo, and its prevalence levelled off at about week 10 (Wharton et al., Diabetes, Obesity and Metabolism, 2022). A median is a midpoint, not a deadline; some episodes were shorter and others longer.

Why semaglutide changes bowel habits

Semaglutide activates the GLP-1 receptor, increasing fullness and changing gastrointestinal movement. The current Wegovy prescribing information says semaglutide delays gastric emptying. A small randomized scintigraphy study gives that mechanism a concrete scale: after 12 weeks, 20 women with obesity and polycystic ovary syndrome had a gastric half-emptying time of 171 minutes with semaglutide 1.0 mg versus 118 minutes with placebo (Jensterle et al., Diabetes, Obesity and Metabolism, 2023). The population was narrow, so the number should not be treated as universal.

The evidence lower in the gut is thinner. In a 2025 case series of 10 people referred for motility testing while taking a GLP-1 medicine, delayed colonic transit appeared in 33% and delayed whole-gut transit in 44%. The three people taking semaglutide 1.0 mg had the three longest gastric emptying times and all had delayed whole-gut transit (Cymbal et al., ACG Case Reports Journal, 2025). Because the participants had suspected gastroparesis or chronic constipation, this supports a possible mechanism but cannot estimate how often it happens.

There is a simpler contributor too. Feeling full sooner can mean less food and less fluid. That leaves less stool bulk and less water available to keep it soft. Constipation may therefore reflect several changes at once, not a single blockage or a sign that the medicine is working better.

Why the timeline differs from nausea and diarrhea

Nausea, vomiting and diarrhea generally peaked around the escalation period in STEP 1–3 and then declined; individual episodes had median durations of 8, 2 and 3 days. Constipation's 47-day median explains why it can feel out of step with the rest. How long GLP-1 nausea lasts owns that symptom and its timeline.

A different GLP-1-based medicine is not automatically an escape hatch. Tirzepatide also changes gut motility and can produce either constipation or diarrhea. The tirzepatide diarrhea guide explains the opposite bowel pattern. A switch between medications belongs in a clinical review because tolerability, response and medical history all matter.

What a prescriber may discuss for relief

The first conversation is usually practical. A multidisciplinary clinical consensus on GLP-1 gastrointestinal effects identifies water, dietary fibre and mobility as the basic constipation measures, while leaving dose reduction or slower escalation to the clinician (Gorgojo-Martínez et al., Journal of Clinical Medicine, 2023). The goal is a routine that is tolerable, not a dramatic correction overnight.

Topic	What the prescriber is trying to learn	Possible clinical response
Fluid	Whether early fullness has quietly reduced drinking	A steady fluid plan suited to the patient's health history
Fibre from food	Whether smaller meals have removed fruit, vegetables, beans or whole grains	A gradual increase; adding a large amount at once can worsen bloating
Movement	Whether activity has fallen as intake or energy changed	Regular gentle activity within the patient's abilities
Titration	Whether symptoms began after an increase and are still disruptive	More time at a tolerated dose, a lower dose or a temporary hold, if the prescriber chooses

The clinician may also review other contributors: a previously irregular bowel pattern, low overall intake, a recent diet change, thyroid disease, or another medication that slows the bowel. A dose change should not be improvised. Semaglutide's dose and escalation schedule are decisions for the patient and prescriber.

When constipation needs a call

Constipation becomes a different problem when it is severe, persistent or paired with signs that material may not be moving through the bowel. As of August 2026, the Wegovy prescribing information tells patients to contact a clinician for severe or persistent gastrointestinal symptoms. It also lists postmarketing reports of ileus, intestinal obstruction and severe constipation including fecal impaction; voluntary reports cannot establish frequency or prove that semaglutide caused an event.

Severe or persistent abdominal pain, repeated vomiting, a markedly swollen abdomen, inability to keep fluids down, or many days without a bowel movement warrant prompt contact with the prescriber. Severe pain or vomiting with an inability to pass stool or gas merits urgent assessment. That is not the moment to keep adding fibre or to wait for the next routine check-in.

What the clinical check-in should settle

A useful check-in establishes when the bowel change began, how it relates to the most recent dose change, whether gas is still passing, and whether pain or vomiting is present. From there, the clinician can separate expected adjustment from a symptom that needs examination or a change in the treatment plan. Whether treatment continues, pauses or changes is a decision for the patient and the prescribing clinician.

At Promise, a licensed provider reviews every request, and not everyone qualifies. If semaglutide is prescribed, that same clinical relationship is where persistent constipation and titration decisions belong.